PMC:6249243 / 20249-20947 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6249243","sourcedb":"PMC","sourceid":"6249243","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6249243","text":"Fig. 5 miR-330-5p suppressed SPRY2 expression to promote HCC growth.\na The proliferation capacity of HepG2anti-miR-330-5p cells with SPRY2 knockdown (HepG2anti-miR-330-5p+shSPRY2) and MHCC97-LmiR-330-5p cells with SPRY2 ectopic expression (MHCC97-LmiR-330-5p+SPRY2) and their control cells was assessed by MTT assay (a), colony formation assay (b), EdU assay (c), and cell cycle assay (d). e The subcutaneous tumor mouse model was used to compare the tumor volume from SPRY2 interfered HepG2anti-miR-330-5p or MHCC97-LmiR-330-5p cells. f The orthotopic HCC mouse model was used and representative bioluminescence images were taken in the eighth week showed that SPRY2 inhibited tumor growth in vivo","divisions":[{"label":"Title","span":{"begin":7,"end":68}}],"tracks":[]}